Cytodyn Inc (CYDY) 0.8000 $CYDY CytoDyn Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cytodyn Inc (CYDY) 0.8000 $CYDY

CytoDyn Announces Investor Call to Provide Update on Clinical Development Strategy
Business Wire - Wed Mar 19, 7:05AM CDT
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company will host a live conference call and webcast with the investment community on Tuesday, March 25, 2014 at 1:30 p.m. PT to provide an update on the Company's clinical development strategy for lead product candidate, PRO 140, including progress with its preparations for its treatment substitution Phase 2b study in patients with Human Immunodeficiency Virus (HIV). PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells, and belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

CytoDyn Files Protocol to FDA for Phase 2b Clinical Study of PRO 140 for Treatment Substitution in Patients with HIV
Close-Up Media - Thu Feb 20, 11:36PM CST
CytoDyn Inc., a biotechnology company focusing on the development of new therapies for combating infection with immune deficiency viruses, said that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

CytoDyn Signs Agreement with Amarex Clinical Research LLC to Prepare Two Phase 2b Clinical Trial Protocols to Explore Two Additional Therapeutic Indications for PRO 140
Business Wire - Tue Jan 28, 7:05AM CST
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company plans to expand its clinical development program for PRO 140 and signed an agreement with Amarex Clinical Research LLC to prepare two Phase 2b clinical trial protocols to explore two additional therapeutic indications for its lead product candidate. One of the new protocols is expected to be completed in the first quarter of 2014 and the second protocol early in the second quarter of 2014. After submission of the Phase 2b clinical trial protocols to the U.S. Food and Drug Administration (FDA), the Company and Amarex will work with the FDA to obtain approval to commence the trials.

CytoDyn to Webcast Presentation at Biotech Showcase 2014 in San Francisco on Monday, January 13, at 2:30 PM Pacific
Business Wire - Wed Jan 08, 7:04AM CST
---Presentation Will Focus on Company's Strategic Priorities and Development Plans for Lead Product Candidate PRO 140-

CytoDyn Announces FDA Approval of Patient Screening for Phase 2b Study with Lead Product Candidate PRO 140 for the Treatment of HIV Type 1
Business Wire - Tue Jan 07, 3:41PM CST
--Study being conducted by leading HIV expert, Jeffrey M. Jacobson, M.D., at Drexel University

CytoDyn Submits Phase IIb Protocol for PRO 140 Clinical Trial to FDA
Business Wire - Wed Oct 30, 2:59PM CDT
CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.

CytoDyn Inc. Appoints David Feigal, M.D., as Chief Medical Officer
Business Wire - Fri Oct 25, 1:35PM CDT
CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced the appointment of Dr. David Feigal as the Company's new Chief Medical Officer.

CytoDyn Inc. Completes $14.5 Million Private Equity Offering
Business Wire - Thu Oct 24, 6:40PM CDT
CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced the completion of its equity capital raise for a total of $14.5 million through a private offering. Additional details about the offering are included in CytoDyn's Current Report on Form 8-K filed today with the Securities and Exchange Commission and available under "Investors--Financial Information" at www.cytodyn.com.

OTC Daily Alert Stock Watch - CytoDyn (OTCQB: CYDY)
WorldStockWire - Thu Aug 15, 10:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

CytoDyn Inc names Anthony D. Caracciolo as board chair
M2 - Tue Jun 18, 6:13AM CDT
Biotechnology company CytoDyn Inc (OTC QB:CYDY) revealed on Monday the appointment of Anthony D. Caracciolo as chairman of the board of directors with immediate effect.

CytoDyn Inc. Appoints Anthony D. Caracciolo as Chairman of the Board of Directors
Business Wire - Mon Jun 17, 3:52PM CDT
CytoDyn Inc. ("CytoDyn") (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that Anthony D. Caracciolo has been appointed Chairman of the Board of Directors effective June 17, 2013. Past Chairman, Gregory A. Gould, will remain a member of the Board of Directors and continue to serve as Chair of the Audit Committee.

CytoDyn Announces Important Milestone Achieved to Initiate Phase IIb Studies
Business Wire - Mon Apr 29, 3:11PM CDT
CytoDyn Inc. ("CytoDyn") (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for the treatment of human immunodeficiency virus (HIV) infection, announced that CytoDyn Inc. and Drexel University have entered into a contract with Ajinomoto Althea, Inc. to formulate CytoDyn's PRO 140 bulk drug substance through a "fill and finish" process resulting in clinical-ready vials to advance its two NIH-funded Phase IIb studies. These trials will be conducted by Drexel University and are funded by over $10 million in grants from the National Institute of Health (NIH). Ajinomoto Althea, Inc. is a contract development and manufacturing company based in San Diego, California.

CytoDyn to Attend BIOCOM Global Life Sciences Partnering Conference
Business Wire - Wed Feb 27, 8:00AM CST
CytoDyn Inc. ("CytoDyn") (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will be presenting an update on the company's technology at the BIOCOM Global Life Sciences Partnering Conference at the Lodge in Torrey Pines, La Jolla, California.

CytoDyn Announces Collaboration with Dr. Bruce Torbett, The Scripps Research Institute, to study PRO 140 in a Pre-exposure Prophylaxis (PrEP) Model of HIV Infection
Business Wire - Tue Feb 26, 10:29AM CST
CytoDyn Inc. ("CytoDyn") (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it has entered into a research collaboration with Dr. Bruce Torbett of The Scripps Research Institute to study CytoDyn's experimental humanized anti-CCR5 antibody PRO 140 in a pre-exposure prophylaxis (PrEP) model of HIV infection.

CytoDyn Announces Investor Update Conference Call on Friday, February 22
Business Wire - Tue Feb 19, 8:00AM CST
CytoDyn Inc. ("CytoDyn") (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will conduct a shareholder update conference call at 10:00 AM PST on Friday, February 22, 2013.

CytoDyn to Attend 31st Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 07, 6:51AM CST
CytoDyn Inc. ("CytoDyn") (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will be presenting an update on the company's technology during the 31st Annual J.P. Morgan Healthcare Conference on January 9, 2013 at 3:15 PM PT. More information regarding the conference can be found at http://www.ebdgroup.com/bts/index.php.

CytoDyn Appoints Former Ambassador to Bahrain as Middle East Business Consultant
Business Wire - Wed Jan 02, 7:52AM CST
CytoDyn Inc. ("CytoDyn") (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it has entered into a consulting agreement with former U.S. Ambassador Sam Zakhem.

CytoDyn Elects Two New Directors and Appoints New Chief Financial Officer
Business Wire - Tue Dec 18, 8:17AM CST
CytoDyn Inc. ("CytoDyn") (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced the election of Michael Nobel, Ph.D., and Allan M. Green, M.D., Ph.D., J.D., to the company's Board of Directors at its annual shareholders meeting held on December 12, 2012. CytoDyn also announced the appointment of Michael D. Mulholland as the company's new Chief Financial Officer, Treasurer and Corporate Secretary, effective December 13, 2012.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Blue Diamond's $1 Billion Brand Meets Farm Realities

Updated Category News Views 126

A Ten-Cent Signal Carries Real Weight A ten-cent edge over the industry benchmark may not excite the cocktail-party crowd, but almond growers notice every penny when fertilizer, power and pest control keep gnawing at the farm gate. Blue Diamond Growers says it delivered payments roughly 10 cents above the benchmark in its latest year, alongside net profit that came in...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 35

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth

Updated Category News Views 196

Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...

Continue Reading
COSCO Shipping Uses CIIE to Put People in the Chain

Updated Category News Views 87

A Supply Chain Is Not Just Steel and Schedules Containers do not shake hands, but the people routing them certainly do. That was the useful, rather human point underneath COSCO SHIPPING's presence at the ninth China International Import Expo in Shanghai: global logistics is a physical business built on relationships that have to survive different languages, markets,...

Continue Reading
Borr’s Q3 Presentation Puts Jack-Up Investors on Watch

Updated Category News Views 39

Jack-up drilling is a rough business to judge from a calendar invite, but Borr Drilling has put a useful marker in the sand. The company is scheduled to present financial results for the three and nine months ended September 30, 2026, at 09:00 New York time, or 15:00 CET, on Thursday, November 19. For holders of BORR, this is less about ceremonial webcast chatter and more...

Continue Reading
MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 115

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 97

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 74

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 48

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 142

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading

Top 5 Most Recently Viewed Articles

Business Jet Steals the Spotlight with Starlink Installation

Updated Category News Views 350

Business Jet Achieves Significant Milestone with Starlink Business Jet has proudly completed the first installation of Starlink on the Embraer Legacy 600 certification aircraft. This innovative achievement signifies a major step in enhancing the inflight connectivity experience for clients, marking the Legacy 600 as a pioneer aircraft equipped with Starlink capabilities....

Continue Reading
Understanding the Importance of Snow Removal for Roof Safety

Updated Category News Views 166

Understanding the Importance of Roof Snow Removal When it comes to maintaining the safety of your home during winter, one crucial task often overlooked is roof snow removal. Roofing expert John Kolarik from Mariage Roofing shares valuable insights on why homeowners should be proactive about this important aspect of winter maintenance. Removing snow from roofs not only...

Continue Reading
Teck Resources Plans Significant Share Buyback Initiative

Updated Category News Views 126

Teck Resources Limited's Normal Course Issuer Bid Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) has exciting news as it prepares to initiate a normal course issuer bid aimed at repurchasing its Class B subordinate voting shares. With the Toronto Stock Exchange’s approval, Teck is set to purchase up to 40 million of these shares, equating to roughly 7.9% of...

Continue Reading
SR Bancorp Sees Fluctuations in Quarterly Income Performance

Updated Category News Views 192

Introduction to SR Bancorp, Inc. SR Bancorp, Inc. (NASDAQ: SRBK), the holding company for Somerset Regal Bank, has recently published its quarterly financial results, reflecting changes in net income and asset growth. In the most recent quarter, the company demonstrated resilience and adaptability amidst fluctuating market conditions. Net Income Overview Financial Results...

Continue Reading
Reddit Inc's Stock Surges: Navigating Mispricing and Strategies

Updated Category News Views 146

Reddit Inc Experiences Remarkable Stock Surge After being under pressure for much of the spring, shares of Reddit Inc (NYSE: RDDT) have rebounded dramatically. The stock experienced a surge of over 50% within a span of just two weeks, decisively breaking out of its previous trading range and reaching all-time highs. This notable rebound is striking, especially considering...

Continue Reading